Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN).

Grace KongSimona Grozinsky-GlasbergMichael S HofmanTim AkhurstAmichay MeirovitzOfra MaimonYodphat KrauszJeremy GodefroyMichael MichaelDavid J GrossRodney J Hicks

Published in: European journal of nuclear medicine and molecular imaging (2018)

Our results indicate high efficacy and morphologic responses with minimal toxicity and very encouraging survival from PRRT in patients with metastatic rectal NEN despite the adverse prognostic features of this cohort. Further prospective PRRT trials are warranted in this subgroup.

Keyphrases

rectal cancer
squamous cell carcinoma
small cell lung cancer
high grade
oxidative stress
metabolic syndrome
bone marrow
mesenchymal stem cells
adipose tissue
insulin resistance
cell therapy
weight loss
open label